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Abstract: The present study aimed to explore whether four single nucleotide polymorphisms 
(SNPs) within the AHI1 gene could be associated with schizophrenia (SCZ) and whether 
they could predict the clinical outcomes in SCZ patients treated with antipsychotics. Four 
hundred twenty-six (426) in-patients with SCZ and 345 controls were genotyped for four 
AHI1 SNPs (rs11154801, rs7750586, rs9647635 and rs9321501). Baseline and clinical 
measures for SCZ patients were assessed through the Positive and Negative Syndrome 
Scale (PANSS). Allelic and genotypic frequencies in SCZ subjects were compared with 
those of controls using the χ2 statistics. The repeated-measure ANOVA was used for the 
assessment of treatment outcomes measured by PANSS changes. The case-control analysis 
did not show any difference in the genotypic distribution of the SNPs, while in the allelic 
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analysis, a weak association was found between the rs9647635 A allele and SCZ. Furthermore, 
in the haplotype analysis, three haplotypes resulted in being associated with SCZ. On the 
other hand, two SNPs (rs7750586 and rs9647635) were associated with clinical improvement 
of negative symptoms in the allelic analysis, although in the genotypic analysis, only trends 
of association were found for the same SNPs. Our findings suggest a possible influence of 
AHI1 variants on SCZ susceptibility and antipsychotic response, particularly concerning 
negative symptomatology. Subsequent well-designed studies would be mandatory to 
confirm our results due to the methodological shortcomings of the present study. 
Keywords: AHI1 gene; polymorphism; schizophrenia; antipsychotic; response 
 
1. Introduction 
Schizophrenia (SCZ) is a severe and chronic psychiatric disorder that represents a major public 
health concern [1]. Family, twin and adoption studies show evidence for a strong genetic component in 
SCZ, with an estimated heritability of about 64% [2]. However, despite the evidence of the strong 
genetic etiology for SCZ, very little is known about the specific genes underlying such a condition. 
Similarly, a genetic contribution for treatment outcome in SCZ has been continuously suggested [1,3]. 
Indeed, the effects of psychopharmacological treatments are mediated by biological processes, which 
are at least partially controlled by genetic factors [4]. Genetic research in SCZ could therefore contribute 
to the prediction of treatment response and side effects in individual patients, thus leading to an 
optimization of treatment, and could help to better understand the mechanisms of the illness, as well [4,5]. 
The Abelson helper integration site-1 (AHI1) locus, which is located on chromosome 6q23 and has 
a genomic size of 213,792 bp, encodes the protein, Jouberin, and is widely expressed in the brain  
(for details, see [6]). Comparative analysis of the AHI1 locus in primates proposes that the gene has 
undergone positive selection during the evolution of the human lineage [7]. AHI1, which is also  
well-known as the mouse orthologue of Jouberin, is a neuronal cytoplasmic protein that binds with 
huntingtin-associated protein 1 (Hap1) and, thereby, formulates a stable protein complex, which is 
important for maintaining the level of tyrosine kinase receptor B (TrkB), which is critical for neuronal 
differentiation and brain development [8,9]. Interestingly, the endogenous TrkB ligand in humans  
(i.e., the brain-derived neurotrophic factor, BDNF) is a survival factor for parvalbumin-positive 
interneurons, which have been shown to be specifically altered in a series of postmortem studies in 
SCZ and are thought to be involved in the physiopathology of the disorder [5,10]. In addition,  
the literature [11–18] proposing the relationship between AHI1 and neuropsychiatric disorders, 
including SCZ, has been continuously increasing. Another interesting point is that AHI1 also may  
be possibly involved in the development of metabolic syndrome, which is important in the 
pharmacological management of SCZ and other neuropsychiatric disorders [19–22]. 
The association of AHI1 with SCZ was first reported in 2003 in an Israeli Arab family sample  
with high incidence of SCZ through a genome-wide linkage scan [23]. This result was subsequently 
replicated in a linkage analysis of a linkage peak on 6q [24] and in a fine-mapping study that identified 
seven markers significantly associated with SCZ [14]. The findings were subsequently replicated in an 
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independent Icelandic case-control study [15] and in a sample of immortalized lymphoblasts of Arab 
Israeli SCZ patients [25]. The 6q region has been linked to SCZ in other studies, as well [15,26–28]. 
Moreover, the AHI1 gene locus has also been linked with autism, which overlaps with a SCZ  
haplotype [29] and is also seen in some patients with Joubert syndrome, a rare autosomal recessive 
disorder presenting brain dysfunction and intellectual impairment, indicating indirectly that the AHI1 
gene may be involved in the crucial process of the neurodevelopmental system [30]. In our previous 
study [31], rs9647635 A/A was more represented in subjects with bipolar disorder as compared with 
major depression and healthy subjects together. rs9647635 A/A was also more represented in patients 
with major depression than in healthy subjects. 
On the basis of the aforementioned evidence, the present paper aims to investigate whether a set of 
SNPs within the AHI1 gene, which were selected on the basis of previous literature data [15,17] or 
because they are Tag SNPs, could be associated with SCZ and to explore whether such variants could 
predict clinical outcome in SCZ patients naturalistically treated with antipsychotics. Taken together,  
the SNPs investigated allow the coverage of 4.3% of the genetic variance of the AHI1 gene, which has 
had 1,105 SNPs validated so far [32]. 
2. Results and Discussion 
The socio-demographic features of the samples, such as gender, age and further clinical and  
socio-demographical variables, are reported in Table 1. For control subjects, only data on gender and 
age were collected. Patients and controls differ with regard to gender and age (both p < 0.001). 
Table 1. Clinical and demographic characteristics of the sample. PANSS, Positive and 
Negative Syndrome Scale. 
Variable  
Schizophrenia 
Controls  
(n = 345) Total Sample  
(n = 426) 
Sample with Follow-up  
(n = 238) 
Gender 
Males 198 (46.5%) 136 (57.1%) 138 (40%) 
Females 181 (42.5%) 102 (42.9%) 207 (60%) 
Missing 47 (11.0%)   
Age (years)  36.2 ± 11.73 37 ± 12.16 43.39 ± 14.05 
PANSS total score 
Baseline 93.91 ± 13.55 94.02 ± 13.95  
Discharge NA 76.63 ± 8.96  
Age at onset (years)  23.65 ± 6.6 23.28 ± 6.5  
Family history of 
psychiatric disorders 
Yes 65 (15.2%) 38 (16.0%)  
No 317 (74.4%) 200 (84.0%)  
Missing 44 (10.3%)   
Suicide attempts 
Yes 73 (17.1%) 46 (19.3%)  
No 309 (72.5%) 192 (80.7%)  
Missing 44 (10.3%)   
Data represent the mean ± the standard deviation or the number (%); NA: Not Available. 
All of the considered SNPs were in Hardy–Weinberg equilibrium (HWE) in the whole sample  
(Table 2). Strong linkage disequilibrium was observed between all SNPs, particularly between 
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rs7750586 and rs9647635, rs11154801 and rs9647635, rs11154801 and rs7750586 (for the linkage 
disequilibrium (LD) plot, see Figure 1. For the position of the investigated SNPs on AHI1 gene and the 
entire gene LD plot see Figure 2). 
Table 2. Genotype and allele frequency of the SNPs under investigation in the present 
study. HWE, Hardy–Weinberg equilibrium. 
SNPs Position a 
HWE’s 
p-Value 
Location  
Schizophrenia 
(n = 426) 
Controls  
(n = 345) 
χ2 p-Value 
Alleles 
rs11154801 
135739355 
1.0 Intron 
C 671 (78.8) 542 (78.5) 
0.01 0.92 
(79549) A 181 (21.2) 148 (21.4) 
rs7750586 
135827673 
0.6839 Promoter 
T 680 (79.8) 551 (79.8) 
0.001 0.98 
(−8770) C 172 (20.2) 139 (20.1) 
rs9647635 
135841056 
0.7021 Intron 
A 718 (84.3) 551 (79.9) 
5.10 0.02 
(22118) C 134 (15.7) 139 (20.1) 
rs9321501 
135641417 
1.0 Intron 
A 634 (74.4) 527 (76.4) 
0.79 0.37 
(77487) C 218 (25.6) 163 (23.6) 
Genotypes 
rs11154801 
135739355 
1.0 Intron 
C/C 266 (62.4) 213 (61.7) 
0.10 0.94 (79549) A/C 139 (32.6) 116 (33.6) 
 A/A 21 (4.9) 16 (4.6) 
rs7750586 
135827673 
0.6839 Promoter 
T/T 273 (64.1) 220 (63.8)  
0.10 0.95 (−8770) C/T 134 (31.5) 111 (32.2) 
 C/C 19 (4.5) 14 (4.0) 
rs9647635 
135841056 
0.7021 Intron 
A/A 302 (70.9)  221 (64.1) 
5.20 0.07 (22118) A/C 114 (26.8) 109 (31.6) 
 C/C 10 (2.3) 15 (4.3) 
rs9321501 
135641417 
1.0 Intron 
A/A 236 (55.4)  204 (59.1) 
1.13 0.57 (77487) A/C 162 (38.0) 119 (34.5) 
 C/C 28 (6.6) 22 (6.4) 
a The relative position to the start codon is given in parenthesis. Data from [32]. In bold nominal associations. 
 
Figure 1. Linkage disequilibrium (LD) plot. The D' values among the SNPs investigated are shown. 
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Figure 2. SNP positions on the AHI gene. 
2.1. Differences between Genotype and Allele Frequencies in SCZ Patients and Healthy Controls 
There were no significant differences in the genotype frequencies of the investigated SNPs between 
the two groups, although a trend of association was found between rs9647635 and SCZ (p = 0.07)  
(Table 2). In the allelic analysis, an association between the rs9647635 A allele and SCZ was found  
(p = 0.02), although it did not survive the false discovery rate (FDR) correction. The result did not 
change after the inclusion of covariates in the analysis. 
There were no further significant differences between genotype and allele frequencies in patients 
with SCZ and healthy controls. Further, in the haplotype analysis, three haplotypes resulted in being 
associated with SCZ (see Table 3), although one of them resulted in being very rare in the control 
sample (ACAC haplotype, frequency in control sample = 0.001). All of the associations survived the 
permutation, and they did not change after the inclusion of covariates. 
Table 3. Haplotype analyses in the present case-control association study. 
rs11154801 rs7750586 rs9647635 rs9321501 
Cases  
Hap-Freq a 
Controls  
Hap-Freq a 
p-
Value 
Sim b  
p-Value 
Odds Ratio 
A C C C 0.14 0.18 0.04 0.04 0.82 (0.62–1.09) 
C T A A 0.70 0.74 0.19 0.18 1 (NA) 
A C C A 0.01 0.02 0.40 0.40 0.77 (0.35–1.69) 
C T A C 0.07 0.05 0.10 0.10 1.46 (0.92–2.30) 
A T A C 0.02 0.01 0.04 0.03 2.45 (0.86–6.99) 
A C A C 0.03 0.001 <0.001 <0.001 18.85 (1.89–187.55) 
a Haplotype frequencies; b Simulated p value, i.e., after permutation; In bold nominal associations. NA: Not applicable. 
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2.2. AHI1 Variants and Clinical Improvement in SCZ Subjects 
With regard to the influence of the investigated polymorphisms on clinical improvement, in the 
genotype analyses, repeated-measures ANOVA did not show any association. On the other hand,  
in the allelic analyses, two SNPs (rs7750586 and rs9647635) were found to be associated with 
improvement at the negative subscale of the Positive and Negative Syndrome Scale (PANSS) 
(respectively p = 0.033 and p = 0.029). Interestingly, the same SNPs showed a trend of association 
with improvement at the PANSS negative subscale, also in the genotypic analyses (respectively  
p = 0.087 and p = 0.09). The results did not change after the inclusion of the covariates in the analyses. 
Nonetheless, no association survived the FDR correction. 
The haplotype analysis did not reveal any significant association with clinical improvement in the 
patient sample (see Table 4). 
Table 4. Haplotype analyses on the improvement of the PANSS total score. 
rs11154801 rs7750586 rs9647635 rs9321501 Hap-Freq p-Value Sim p-Value 
A C C C 0.14 0.17 0.17 
A C C A 0.02 0.48 0.42 
C T A A 0.72 0.68 0.68 
A T A C 0.02 0.52 0.48 
A C A C 0.02 0.45 0.41 
C T A C 0.07 0.41 0.41 
No further genotypes, alleles and haplotypes under investigation were significantly associated with 
clinical improvement, measured through the PANSS scale and its subscales. 
The present study aimed to investigate whether four SNPs within the AHI1 gene could be 
associated with SCZ and whether the same variants could predict clinical outcomes in SCZ patients 
treated with antipsychotics. 
In the case-control analysis, we failed to find any association among the SNPs investigated and  
the risk of SCZ. Only a weak association was found between the A allele of rs9647635 and SCZ. 
Nonetheless, three haplotypes of the four SNPs investigated were associated with SCZ. Torri et al. [13] 
identified 6q23.3 as a possible candidate region for SCZ and subsequently validated their finding by 
performing a fine mapping of the entire originally identified linkage region [14]. The best association 
findings were detected in a region including the AHI1, PDE7B and MAP7 genes. The strongest 
associated SNPs within this region were rs11154801 and rs7759971. These SNPs are included in a 
region of approximately 500 kb encompassing the AHI1 and BC040979 genes, which map very close 
to each other, within a 61-bp interval, and lie in a very high LD region that extends downstream of  
the 5' of AHI1 distally. Torri et al. [13] hypothesized that this region could contain sequences possibly 
having a regulatory role for both AHI1 and PDE7B, given that the two genes are transcribed in  
the opposite direction. Consistently, Slonimsky et al. showed an association between the rs9321501 
genotype of the AHI1 gene and the AHI1 brain expression in the postmortem brain of SCZ subjects, 
suggesting a possible regulatory role for this SNP or for some variants linked with it [25]. 
Unfortunately, in the present study, we failed to replicate the previous findings, since the SNPs under 
investigation were not associated with the risk of developing SCZ. This could be due, at least partially, 
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to the different ethnicity of our sample compared to previous studies, which were mainly performed on 
the Caucasian population. However, the results from haplotype analysis partially confirm the previous 
results. Nonetheless, our samples were relatively small for a genetic case-control study, and according 
to the power analysis, our statistical power allows detecting differences between groups equal to about 
an OR of 1.6, which is very uncommon for a single genetic variant in a multi-factorial disorder,  
such as SCZ. Thus, our negative findings may likely reflect the small power of the samples in the 
exam, rather than a real absence of the effects of the variants in exam. Therefore, further studies with 
larger samples or a meta-analysis are needed to clarify the role of the AHI1 gene in the determination 
of the risk for SCZ. 
Further, in the present study, we failed to find any effect of the SNPs in the exam on the 
antipsychotic response measured by the PANSS scale. However, in the allelic analyses, we found that 
two SNPs, rs7750586 and rs9647635, were associated with the improvement at the negative subscale 
of the PANSS. Although these associations were weak and did not survive the FDR correction,  
we have to consider that our study is the first one investigating the relationship among AHI1 variants 
and antipsychotic response in SCZ patients. Therefore, our results support further investigations of this 
gene in the antipsychotic pharmacogenetic field, particularly concerning negative symptomatology. 
This could be very interesting, since the negative symptoms are known to be less responsive to 
antipsychotic treatments; thus, the detection of the predictor of the response for these deleterious 
symptoms may be useful from a clinical point of view, since it could allow planning specific 
treatments for those patients who respond worse to antipsychotic drugs. Interestingly, rs7750586 was 
reported to be associated with the risk of SCZ in three previous studies [14,15,17]; particularly, in a 
large case-control association study performed on two different samples from Germany and Spain, 
rs7750586 was associated with SCZ, both in the genotype and in the allelic analyses [17]. Contrary to 
the findings mentioned above, we did not observe any significant association between rs7750586 and 
SCZ susceptibility. On the other hand, we observed an association between this SNP and improvement 
in negative symptomatology, as well as for rs9647635. Considering the relevance of negative symptoms 
for SCZ patients’ outcome, our results may partially support the importance of AHI1 gene variants in 
the pathogenesis of SCZ itself and, particularly, in the determination of the antipsychotic response. 
There are many reasons that could explain the discrepancy of our results compared to literature 
data, and these represent the main limitations of the present work. Firstly, candidate gene studies,  
such as the present one, are associated with a high likelihood of false positive findings [33]. This is 
particularly true for studies with relatively small sample sizes, like our one, which may have a quite 
low statistical power. Further replications in independent samples are needed to confirm our results.  
A further concern is related to the use of different antipsychotics with different mechanisms of action 
for each cohort of patients, which do not allow one to draw definitive conclusions with regard to the 
influence of the SNPs under investigation upon specific or classes of medications. However,  
our decision to include patients treated with different drugs could have the advantage of being closer to 
“real-world” clinical practice. Additionally, our diagnosis of psychiatric disorder was based on current 
DSM-IV criteria and also complemented by a structured interview with Mini-International 
Neuropsychiatric Interview (MINI). However, with this instrument, there is neither the ability to rule 
out all possibilities that patients with SCZ could switch in the future to a diagnosis of bipolar disorders, 
nor to exclude a possible switch to schizoaffective disorder. Such issues are important for genetic 
Int. J. Mol. Sci. 2015, 16 2524 
 
 
studies, as shown by recent findings suggesting that bipolar disorder and SCZ could share many 
important risk genes [2]. Furthermore, we asked healthy controls to report only known psychiatric 
disorders among first- and second-degree relatives, thus limiting the possibility to detect whether  
sub-threshold or untreated psychiatric disorders among family members of healthy control subjects 
could exist. Moreover, the healthy control sample differed from the patient sample, both for gender 
and age, and this could reflect a sort of selection bias, because volunteers were more often female and 
being of an older age than the patients. However, these differences may be just due to a better 
inclination of this kind of subject in the Korean population to participate as a volunteer in research 
studies, rather than to other possible selection biases. A further possible limitation of the present study 
could be imputed to the incomplete coverage of genes under investigation. Finally, sample heterogeneity 
could not be completely excluded, although our subjects were all native Koreans, which are considered 
to be genetically homogenous [26]. 
3. Methods 
3.1. Subjects 
The sample under investigation in the present study comprised 426 in-patients with SCZ who were 
consecutively recruited at the Department of Psychiatry of the Catholic University of Korea College  
of Medicine, Seoul, Korea. Patients were eligible for inclusion if they had a documented clinical 
diagnosis of SCZ according to the DSM-IV criteria, as assessed by the Mini-International 
Neuropsychiatric Interview (MINI) [34]. Patients were excluded if they currently had comorbid 
psychiatric disorders other than SCZ (e.g., bipolar disorder, substance-related disorders, etc.) and 
unstable medical/neurological conditions. Follow-up evaluations were available for 238 SCZ patients; 
thus, this subsample was used to perform pharmacogenetic analyses. A healthy control of 345 Koreans 
underwent the same assessment as did psychiatric patients for the exclusion of possible psychiatric 
disorders, and they were also asked for the presence of any known psychiatric disorder in first- and 
second-degree relatives. All SCZ patients admitted to the hospital were assessed by trained 
psychiatrists for the severity of illness at baseline and at discharge by the administration of 
psychometric questionnaires. In particular, SCZ severity was assessed by the administration of the 
Positive and Negative Symptoms Scale (PANSS) [35]. The raters were trained with specific 
instruments with good inter-rater reliability (k > 0.8). Additionally, the following clinical and 
demographic variables were recorded for all of the patients recruited: gender, age, age at onset, family 
history of psychiatric disorders, lifetime suicide attempts, duration of admission, drugs at discharge 
and concomitant anxiolytics. The study protocol was approved by the institutional review board 
(Approval Number HC10TISI0031). 
3.2. Statistical Analyses 
Traditional statistical analyses were performed using the “Statistica” package (StatSoft I. STATISTICA 
7.0 per Windows: StatSoft, Inc., Tulsa, OK, USA, 1984–2004), while the test for associations using  
multi-marker haplotypes was performed using the statistic environment “R cran”, package “haplo.score” 
(http://cran.r-project.org/). The main outcome measures of the present study were: (1) differences 
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among genotypic and allelic frequencies in patients with SCZ compared with controls; and (2) the 
possible influence of the 4 SNPs under investigation on clinical improvement, as measured with the 
PANSS total score in SCZ patients. Further sub-outcomes of interest included improvement on the 
PANSS subscale scores (positive, negative and general subscales) in SCZ patients. Although the 
genotype analysis was the primary analysis, we decided to perform also allelic and haplotype analyses 
in order to better elucidate the associations among the phenotypes of interest and the genetic variants 
investigated. Indeed, in this way, we better understand the role of a single allele, as well as the 
potential additive effects among the genetic variants investigated. 
Differences in the allelic and genetic frequencies between healthy subjects and patients were 
calculated using the χ2 statistics (or Fisher’s exact test). The repeated measures ANOVA was used to 
investigate the association among genotypes and the variation over time of the PANSS total score.  
In the case of positive findings, the following clinical variables were added as covariates in order to 
investigate possible confounders: gender, age, age at onset, family history of psychiatric disorders, 
lifetime suicide attempts, duration of admission, medications at discharge and concomitant anxiolytics. 
Haploview 4.2 (Daly Lab at the Broad Institute, Cambridge, MA, USA) was used to generate a linkage 
disequilibrium (LD) map and to test for Hardy–Weinberg equilibrium (HWE) [36]. Gender, age, age at 
onset, family history of psychiatric disorders, lifetime suicide attempts, duration of admission, drugs at 
discharge and concomitant anxiolytics were added as covariates in the case of positive findings. 
Permutations (n = 100.000) were performed to estimate the global significance of the results for all 
haplotype analysis. Only haplotypes with >1% prevalence in the patient sample were included in the 
analysis because of the relatively small size of our sample, which did not allow for the performance of 
an adequate analysis on rare haplotypes. All p-values were 2-tailed. In order to reduce the likelihood of 
false positive findings, statistical significance was set at the level of 0.01, as calculated by the means of 
the false discovery rate (FDR), which allow for a correction of multiple testing without being as 
conservative as the Bonferroni correction [37]. G-Power (http://www.psycho.uni-duesseldorf.de/aap/ 
projects/gpower/) was employed to perform the power analysis. With these parameters (p = 0.01),  
we had a sufficient power (0.80) to detect small-medium effect sizes (w = 0.125), which, as an example, 
corresponded to an odds ratio (OR) of 1.6 between the group of patients and the group of controls. 
3.3. Genotyping 
Genomic DNA was extracted from blood by standard methods and quantified. High-throughput 
genotyping using a pyrosequencer (Biotage AB, Uppsala, Sweden) was used for genotyping the four 
SNPs (rs11154801, rs7750586, rs9647635, rs9321501) of AHI1 under investigation. PCR primers 
(Bioneer, Daejeon, Korea) and sequencing primers (Bioneer) used for the pyrosequencing assay were 
designed by using the Pyrosequencing Assay Design Software v.1 (Biotage), and 1 primer of each 
primer set was biotinylated. 
4. Conclusions 
In conclusion, our study partially confirms a possible role of AHI1 gene variability in SKZ 
susceptibility and preliminarily suggests an association between AHI1 gene variants and clinical 
outcomes in SCZ patients. In particular, rs7750586 and rs9647635 seem to be the most promising 
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candidate polymorphisms. However, further research is needed to confirm and extend our findings,  
in particular subsequent well-designed, adequately-powered pharmacogenetic research will be 
necessary (e.g., covering a huge number of SNPs, expanding to larger portions of the gene, prospective 
design and unified treatment with the same antipsychotics). 
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